Johns Hopkins Study: Early Treatment With Plasma May Reduce Long COVID Risk

Johns Hopkins-led research finds early treatment with plasma from recovered COVID-19 patients reduces “long COVID” risks, with inflammation-inducing interleukin-6 (IL6) playing a key role in…